Upstream Bio Management
Management criteria checks 1/4
Upstream Bio's CEO is E. Sutherland, appointed in Apr 2024, has a tenure of 1.92 years. total yearly compensation is $9.24M, comprised of 4.4% salary and 95.6% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $632.10K. The average tenure of the management team and the board of directors is 1.9 years and 3.7 years respectively.
Key information
E. Sutherland
Chief executive officer
US$9.2m
Total compensation
| CEO salary percentage | 4.41% |
| CEO tenure | 1.9yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.9yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data
Feb 12Upstream Bio (NASDAQ:UPB) Is In A Good Position To Deliver On Growth Plans
Jul 27
Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent
Apr 17We Think Upstream Bio (NASDAQ:UPB) Can Afford To Drive Business Growth
Apr 12Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation
Dec 16Upstream Bio: Attractive, But Let's Wait For More Data And Lock-Up Expiry
Dec 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$143m |
| Sep 30 2025 | n/a | n/a | -US$136m |
| Jun 30 2025 | n/a | n/a | -US$110m |
| Mar 31 2025 | n/a | n/a | -US$90m |
| Dec 31 2024 | US$9m | US$408k | -US$76m |
Compensation vs Market: E.'s total compensation ($USD9.24M) is above average for companies of similar size in the US market ($USD2.40M).
Compensation vs Earnings: Insufficient data to compare E.'s compensation with company performance.
CEO
E. Sutherland (55 yo)
Dr. E. Rand Sutherland, MD, MPH, has been a Director of Krystal Biotech, Inc. from January 2022. Dr. Sutherland serves as Chief Executive Officer and Director at Upstream Bio, Inc. since April 2024. Dr. Su...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$9.24m | 0.13% $ 632.1k | |
| CFO & COO | 2yrs | US$3.01m | 0.054% $ 257.0k | |
| Senior VP | 1.3yrs | US$1.53m | 0.030% $ 143.3k | |
| Chief Technology Officer | less than a year | no data | no data | |
| Director of Corporate Communications & Investor Relations | no data | no data | no data | |
| Senior Vice President of People & Culture | 1.9yrs | no data | no data | |
| Chief Business Officer | 4.4yrs | no data | 0.045% $ 210.7k | |
| Chief Medical Officer and Head of Research & Development | 3.9yrs | US$823.24k | 0.0029% $ 13.7k | |
| Senior Vice President of Regulatory Affairs & Quality | 3.4yrs | no data | no data | |
| VP & Head of Biometrics | 3.2yrs | no data | no data | |
| VP & Head of Clinical Development | 1.8yrs | no data | no data | |
| Senior Vice President of Clinical Operations & Medical Writing | 1.8yrs | no data | no data |
Experienced Management: UPB's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$9.24m | 0.13% $ 632.1k | |
| Independent Director | 4.4yrs | US$228.14k | no data | |
| Independent Chairman of the Board | 4.3yrs | US$816.29k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$228.69k | 0% $ 0 | |
| Independent Director | no data | US$458.98k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$228.47k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$257.43k | 0% $ 0 |
Experienced Board: UPB's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/30 19:10 |
| End of Day Share Price | 2026/03/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Upstream Bio, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Cory Kasimov | Evercore ISI |
| Tessa Romero | J.P. Morgan |
| Joseph Catanzaro | Mizuho Securities USA LLC |